Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Lavipharm's operating assets for the quarter that ended in Dec. 2025 was €124.12 Mil. Lavipharm's operating liabilities for the quarter that ended in Dec. 2025 was €41.14 Mil. Lavipharm's Total Assets for the quarter that ended in Jun. 2025 was €126.65 Mil. Therefore, Lavipharm's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.66.
Lavipharm Scaled Net Operating Assets Related Terms
Lavipharm Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Lavipharm's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BXA0 vs ZTS, UTHR, VTRS: Scaled Net Operating Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lavipharm Scaled Net Operating Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lavipharm's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Lavipharm's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.66 mean?
Lavipharm (FRA:BXA0) has a Scaled Net Operating Assets of 0.66 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Lavipharm and its competitors.
Is Lavipharm's Scaled Net Operating Assets too high?
Lavipharm's current Scaled Net Operating Assets is 0.66. Overall, Lavipharm has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lavipharm's Scaled Net Operating Assets compare to ZTS and UTHR?
Lavipharm's Scaled Net Operating Assets of 0.66 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Lavipharm and its competitors. Lavipharm's current Scaled Net Operating Assets is 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lavipharm stock overvalued right now?
Based on GuruFocus' analysis, Lavipharm (FRA:BXA0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.03, compared to a current price of €1.55 — trading 50.5% above its estimated fair value. The current Scaled Net Operating Assets is 0.66. Lavipharm's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Lavipharm (FRA:BXA0), the current Scaled Net Operating Assets is 0.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lavipharm (FRA:BXA0) Overvalued in 2026?
Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued.
The current stock price of €1.55 is trading 50.5% above its estimated GF Value™ of €1.03.
GuruFocus considers Lavipharm to be Significantly Overvalued.
Key valuation signals for FRA:BXA0:
Scaled Net Operating Assets: 0.66
GF Value™: €1.03 vs. price of €1.55 (50.5% above fair value)
No single metric tells the full story. See the FRA:BXA0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
79GF Score
Get the complete analysis for FRA:BXA0
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BXA0 has been successfully added to your 
